Ibrutinib (Imbruvica®) for previously untreated CLL

Assessment Status Rapid Review Complete
Drug Ibrutinib
Brand Imbruvica®
Indication For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.
Assessment Process
Rapid review commissioned 02/08/2016
Rapid review completed 24/08/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

Not considered cost-effective due to non-submission of full pharmacoeconomic assessment.